Financial assistance

Global Cancer Immunotherapy Market (2022 To 2027)

DUBLIN, April 6, 2022 /PRNewswire/ — The “Cancer Immunotherapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to from ResearchAndMarkets.com offer.

Research and Markets Logo

world cancer immunotherapy the market reached a value of US$96.6 billion in 2021. Looking ahead, the publisher expects the market to reach a value of US$167.5 billion by 2027 presenting a CAGR 9.10% over the 2022-2027 period. Keeping in mind the uncertainties of COVID-19, we continuously monitor and assess the direct and indirect influence of the pandemic. This information is included in the report as a major market contributor.

Cancer is a preventable disease beginning in any organ or tissue of the body due to abnormal cell growth that invades adjacent parts of the body and spreads to other organs. It is one of the leading causes of death worldwide, which is now treated with cancer immunotherapy. Cancer immunotherapy offers more benefits than conventional tumor therapy which can prolong progression-free survival (PFS) and overall survival (OS). It can be combined with radiotherapy, chemotherapy, surgery or targeted therapies to improve their effectiveness. Apart from this, as it enables the immune system to recognize, prevent, control and eliminate cancer, cancer immunotherapy finds many applications in hospitals, cancer research centers and clinics. of the whole world.

There is currently an increase in the number of people with cancer across the world. This, in confluence with the booming healthcare sector, represents one of the key factors propelling the growth of the market. Additionally, there are fewer side effects associated with cancer immunotherapy. As a result, there is a significant increase in the use of monoclonal antibodies to treat different types of cancer by selectively attacking cancer cells.

This, coupled with the growing prevalence of multiple myeloma and melanoma, is catalyzing the demand for cancer immunotherapy. Additionally, prominent players sponsor Patient Assistance Programs (PAPs) that provide financial assistance to low-income individuals to augment existing prescription drug coverage. This, in turn, positively influences the market. Other factors enhancing the growth of the market are technological advancements in clinical therapies, extensive research and development (R&D) activities, and introduction of advanced variants with enhanced treatment efficacy and effectiveness.

Competitive Landscape:

The competitive landscape of the industry was also examined along with the profiles of major players i.e. Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG , GlaxoSmithKline Plc. , Johnson & Johnson, Merck KGAA, Novartis AG, Pfizer Inc., Sanofi and Seagen Inc.

Answers to key questions in this report:

  • How has the global cancer immunotherapy market performed so far and how will it perform in the coming years?

  • What has been the impact of COVID-19 on the Global Cancer Immunotherapy Market?

  • What are the main regional markets?

  • What is the market breakdown by type of therapy?

  • What is the market breakdown by application?

  • What is the market breakdown by end user?

  • What are the different stages of the industry value chain?

  • What are the key drivers and challenges in the industry?

  • What is the structure of the global cancer immunotherapy market and who are the key players?

  • How competitive is the industry?

Main topics covered:

1 Preface

2 Scope and methodology

3 Executive summary

4 Presentation
4.1 Overview
4.2 Key Industry Trends

5 Global Cancer Immunotherapy Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakdown by Treatment Type
6.1 Monoclonal antibodies
6.1.1 Market trends
6.1.2 Market Forecast
6.2 Cancer vaccines
6.2.1 Market trends
6.2.2 Market Forecast
6.3 Checkpoint inhibitors
6.3.1 Market trends
6.3.2 Market Forecast
6.4 Immunomodulators
6.4.1 Market trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market trends
6.5.2 Market Forecast

7 Market Breakdown by Application
7.1 Lung cancer
7.1.1 Market trends
7.1.2 Market Forecast
7.2 Breast cancer
7.2.1 Market trends
7.2.2 Market Forecast
7.3 Colorectal cancer
7.3.1 Market trends
7.3.2 Market Forecast
7.4 Melanoma
7.4.1 Market trends
7.4.2 Market Forecast
7.5 Prostate cancer
7.5.1 Market trends
7.5.2 Market Forecast
7.6 Head and neck cancer
7.6.1 Market trends
7.6.2 Market Forecast
7.7 Others
7.7.1 Market trends
7.7.2 Market Forecast

8 Market Breakdown by End User
8.1 Hospitals
8.1.1 Market trends
8.1.2 Market Forecast
8.2 Cancer research centers
8.2.1 Market trends
8.2.2 Market Forecast
8.3 Clinics
8.3.1 Market trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market trends
8.4.2 Market Forecast

9 Market Breakdown by Region

10 SWOT Analysis

11 Value chain analysis

12 Analysis of the five forces of carriers

13 Price Analysis

14 Competitive landscape
14.1 Market structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Amgen Inc.
14.3.1.1 Company overview
14.3.1.2 Product portfolio
14.3.1.3 Finance
14.3.1.4 SWOT Analysis
14.3.2 AstraZeneca plc
14.3.2.1 Presentation of the company
14.3.2.2 Product portfolio
14.3.2.3 Finance
14.3.2.4 SWOT Analysis
14.3.3 Bayer AG
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Finance
14.3.3.4 SWOT Analysis
14.3.4 Bristol-Myers Squibb Company
14.3.4.1 Company Overview
14.3.4.2 Product portfolio
14.3.4.3 Finance
14.3.4.4 SWOT Analysis
14.3.5 Eli Lilly and company
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Finance
14.3.5.4 SWOT Analysis
14.3.6 F. Hoffmann-La Roche AG
14.3.6.1 Company Overview
14.3.6.2 Product portfolio
14.3.6.3 SWOT Analysis
14.3.7 GlaxoSmithKline Plc
14.3.7.1 Company Overview
14.3.7.2 Product portfolio
14.3.7.3 Finance
14.3.7.4 SWOT Analysis
14.3.8 Johnson & Johnson
14.3.8.1 Company Overview
14.3.8.2 Product portfolio
14.3.8.3 Finance
14.3.8.4 SWOT Analysis
14.3.9 Merck KGAA
14.3.9.1 Company Overview
14.3.9.2 Product portfolio
14.3.9.3 Finance
14.3.9.4 SWOT Analysis
14.3.10 Novartis AG
14.3.10.1 Company Overview
14.3.10.2 Product portfolio
14.3.10.3 Finance
14.3.10.4 SWOT Analysis
14.3.11 Pfizer Inc.
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Finance
14.3.11.4 SWOT Analysis
14.3.12 Sanofi
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
14.3.12.3 Finance
14.3.12.4 SWOT Analysis
14.3.13 Seagen inc.
14.3.13.1 Company Overview
14.3.13.2 Product Portfolio
14.3.13.3 Finance
14.3.13.4 SWOT Analysis

For more information on this report, visit https://www.researchandmarkets.com/r/a6krj5

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1904
Fax (outside the US): +353-1-481-1716

Quote

Quote

Show original content:https://www.prnewswire.com/news-releases/global-cancer-immunotherapy-market-2022-to-2027—industry-trends-share-size-growth-opportunity-and-forecasts-301519014.html

SOURCE Research and Markets